Zolmitriptan (oral): Difference between revisions
Gerald Chi (talk | contribs) m (Changed protection level for "Zolmitriptan" ([Edit=Allow only autoconfirmed users] (expires 02:07, 19 February 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 02:07, 19 February 2014 (UTC)))) |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 1: | Line 1: | ||
{{drugbox | {{drugbox | ||
| IUPAC_name = (4''S'')-4-{[3-(2-dimethylaminoethyl)-1''H''-indol-5-yl]methyl}-<br>1,3-oxazolidin-2-one | | IUPAC_name = (4''S'')-4-{[3-(2-dimethylaminoethyl)-1''H''-indol-5-yl]methyl}-<br>1,3-oxazolidin-2-one | ||
| Line 24: | Line 23: | ||
| routes_of_administration = Oral, nasal spray | | routes_of_administration = Oral, nasal spray | ||
}} | }} | ||
==Overview== | |||
'''Zolmitriptan''' is an oral, selective [[Serotonin receptor agonist]], of the [[serotonin receptor]] 1B/1D (5-HT<sub>1B</sub>/<sub>1D</sub>). It is a second-generation [[triptan]], used in the acute treatment of [[migraine]] attacks with or without [[aura (symptom)|aura]] and [[cluster headache]]s. | '''Zolmitriptan''' is an oral, selective [[Serotonin receptor agonist]], of the [[serotonin receptor]] 1B/1D (5-HT<sub>1B</sub>/<sub>1D</sub>). It is a second-generation [[triptan]], used in the acute treatment of [[migraine]] attacks with or without [[aura (symptom)|aura]] and [[cluster headache]]s. | ||
Zolmitriptan is marketed by [[AstraZeneca]] with the brand names '''Zomig''', '''Zomigon''' (Greece & Argentina), '''AscoTop''' (Germany) and '''Zomigoro''' (France). In 2005, AstraZeneca generated $352 million in sales with Zomig. | Zolmitriptan is marketed by [[AstraZeneca]] with the brand names '''Zomig''', '''Zomigon''' (Greece & Argentina), '''AscoTop''' (Germany) and '''Zomigoro''' (France). In 2005, AstraZeneca generated $352 million in sales with Zomig. | ||
== Description == | ==Description== | ||
Zolmitriptan is a synthetic [[tryptamine]] derivative and appears as a white powder that is readily soluble in water. | Zolmitriptan is a synthetic [[tryptamine]] derivative and appears as a white powder that is readily soluble in water. | ||
== Indications== | ==Indications== | ||
Zolmitriptan is used for the acute treatment of migraines with or without aura in adults. Zolmitriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. | Zolmitriptan is used for the acute treatment of migraines with or without aura in adults. Zolmitriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. | ||
Zolmitriptan comes in both a swallowable and oral disintegrating tablet. People who get migraines from aspartame should not use the disintegrating tablet (Zomig ZMT), which contains aspartame. | Zolmitriptan comes in both a swallowable and oral disintegrating tablet. People who get migraines from aspartame should not use the disintegrating tablet (Zomig ZMT), which contains aspartame. | ||
== Contraindications and | ==Contraindications and Precautions== | ||
Zolmitriptan should not be given to patients with ischemic heart disease ([[angina pectoris]], history of [[myocardial infarction]], or documented silent ischemia) or to patients who have symptoms or findings consistent with ischemic heart disease, [[coronary artery vasospasm]], including [[Prinzmetal's angina]], or other significant underlying cardiovascular disease. | Zolmitriptan should not be given to patients with ischemic heart disease ([[angina pectoris]], history of [[myocardial infarction]], or documented silent ischemia) or to patients who have symptoms or findings consistent with ischemic heart disease, [[coronary artery vasospasm]], including [[Prinzmetal's angina]], or other significant underlying cardiovascular disease. | ||
| Line 43: | Line 48: | ||
Concurrent administration of [[MAOI]] or use of zolmitriptan within 2 weeks of discontinuation of MAO-A inhibitor therapy is contraindicated. | Concurrent administration of [[MAOI]] or use of zolmitriptan within 2 weeks of discontinuation of MAO-A inhibitor therapy is contraindicated. | ||
== Adverse | ==Adverse Reactions== | ||
The Zomig ZMT dissolvable pill contains aspartame, and should be avoided by anyone sensitive to that ingredient. | The Zomig ZMT dissolvable pill contains aspartame, and should be avoided by anyone sensitive to that ingredient. | ||
| Line 52: | Line 57: | ||
==References== | ==References== | ||
*{{cite journal | *{{cite journal | ||
|journal = Drugs Today | |journal = Drugs Today | ||
| Line 62: | Line 68: | ||
|author =MacGregor, E.A.}} | |author =MacGregor, E.A.}} | ||
== External | ==External Links== | ||
*[http://www.zomig.com Zomig Information Site (USA)] | *[http://www.zomig.com Zomig Information Site (USA)] | ||
*[http://www.zomig.info International Zomig Information for Health Care Professionals] | *[http://www.zomig.info International Zomig Information for Health Care Professionals] | ||
| Line 70: | Line 76: | ||
[[Category:Triptans]] | [[Category:Triptans]] | ||
Revision as of 02:57, 10 February 2014
| File:Zolmitriptan.svg | |
| File:Zomitriptan.jpg | |
| Clinical data | |
|---|---|
| Pregnancy category | |
| Routes of administration | Oral, nasal spray |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 40% (oral) |
| Protein binding | 25% |
| Elimination half-life | 3 hours |
| Excretion | Renal (65%) and fecal (35%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C16H21N3O2 |
| Molar mass | 287.357 g/mol |
Overview
Zolmitriptan is an oral, selective Serotonin receptor agonist, of the serotonin receptor 1B/1D (5-HT1B/1D). It is a second-generation triptan, used in the acute treatment of migraine attacks with or without aura and cluster headaches.
Zolmitriptan is marketed by AstraZeneca with the brand names Zomig, Zomigon (Greece & Argentina), AscoTop (Germany) and Zomigoro (France). In 2005, AstraZeneca generated $352 million in sales with Zomig.
Description
Zolmitriptan is a synthetic tryptamine derivative and appears as a white powder that is readily soluble in water.
Indications
Zolmitriptan is used for the acute treatment of migraines with or without aura in adults. Zolmitriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine.
Zolmitriptan comes in both a swallowable and oral disintegrating tablet. People who get migraines from aspartame should not use the disintegrating tablet (Zomig ZMT), which contains aspartame.
Contraindications and Precautions
Zolmitriptan should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's angina, or other significant underlying cardiovascular disease.
Zolmitriptan may increase blood pressure, it should not be given to patients with uncontrolled hypertension, should not be used within 24 hours of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-type medication like dihydroergotamine or methysergide, and should not be administered to patients with hemiplegic or basilar migraine.
Concurrent administration of MAOI or use of zolmitriptan within 2 weeks of discontinuation of MAO-A inhibitor therapy is contraindicated.
Adverse Reactions
The Zomig ZMT dissolvable pill contains aspartame, and should be avoided by anyone sensitive to that ingredient.
Serious cardiac events, including myocardial infarction, have been associated with zolmitriptan. These are, however, rare.
Reported minor adverse reactions include: hypesthesia, paresthesia (all types), warm and cold sensations, chest pain, throat and jaw tightness, dry mouth, dyspepsia, dysphagia, nausea, somnolence, vertigo, asthenia, myalgia, myasthenia and sweating.
References
- MacGregor, E.A. (1998). "Zolmitriptan clinical studies". Drugs Today. 34 (12): 1027–1033. doi:10.1358/dot.1998.34.12.487488.
External Links
- Pages with script errors
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Triptans